All Type of News
Multinational logistics companies aiming for Korean pharma market
The domestic pharmaceutical distribution market has been threatened by multinational logistics companies.
Cardinal Health started to have a business in Korea as signing a distribution agreement with Severance Hospita...
MFDS recommends restricted usage of Hanmi’s Olita Tab for terminal cancer patientsThe Ministry of Food and Drug Safety(MFDS) recommended restricted usage of the Hanmi Pharm’s non-small cell lung cancer therapy ‘Olita Tab,’ which had a death patient during cli... |
MFDS, “The U.S. and Europe also exercise the conditional approval system of Phase 3 clinical trial”
It was observed there were 34 products which acquired approval with the same condition in process of Phase 3 clinical trials like the recently-issued Hanmi Pharm’s non-small cell lung cancer therapy ‘Olita Tab’
Moreo...
Hanmi will sincerely exercise committee’s decision on Olita TabHanmi Pharm announced it respects the decision of the Central Drug Deliberation Committee and will sincerely exercise the safety control measure.
Previously, the Ministry of Fo... |
Industry shocked by first imprisonment on head director of pharma company
A head director of a pharmaceutical company was sentenced imprisonment for the pharmaceutical company-doctor rebate case.
According to the industry concerned, the court was known to sentence the director, who was jai...
Former CEO of Takeda Pharmaceuticals Korea joins in IT venture as president
A company specializing in providing solutions based on smart devices, Appknot(CEO Woo-Yong Jang) announced appointment of the former president of Takeda Pharmaceuticals Korea, Choon-Yup Lee, as of the 1st of October.
...
Boehringer returns license of EGFR targeted therapy Olmutinib to Hanmi
Over the previous official announcement of the ‘Partnership Agreement before Technology Introduction’ containing terms and conditions that Boehringer Ingelheim has the exclusive right for every indication of ‘HM61713’...
Hanmi, “Failure experience of Olmutinib is the most valuable asset”Hanmi Pharm held a press conference related to the recent olmutinib issue on the 2nd at its head office located in Songpa-gu, Seoul, and answered to questions about Boehringer I... |
Why did Hanmi get caught in dilemma?
Hanmi Pharm gets in the focus of controversy as being associated with the technology export of an antibody of KRW 1 trillion with Genentech while having issues with Boehringer Ingelheim which decided to return the lic...
MFDS restricts prescription of Hanmi Pharm’s 27th new Korean drug, ‘Olita Tab’
The 27th new Korean drug developed by Hanmi Pharm, ‘Olita Tab’ was restricted to prescribe for new patients as encountering to an adverse response which was not reflected in its clinical trials.
On the 30th, the Min...
Which are outstanding tetravalent vaccines even for the young?
Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer
Who will be the next Pharmaceutical Safety Bureau Director?
Celltrion completes clinical trials for Remsima SC for European approval
Sales listed pharmas made in the first half of the year
April
January
February
March
April
May
June
July
August
September
October
November
December
2025
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2050
| Sun | Mon | Tue | Wed | Thu | Fri | Sat |
|---|---|---|---|---|---|---|
30 | 31 | 1 | 2 | 3 | 4 | 5 |
6 | 7 | 8 | 9 | 10 | 11 | 12 |
13 | 14 | 15 | 16 | 17 | 18 | 19 |
20 | 21 | 22 | 23 | 24 | 25 | 26 |
27 | 28 | 29 | 30 | 1 | 2 | 3 |
00:00
01:00
02:00
03:00
04:00
05:00
06:00
07:00
08:00
09:00
10:00
11:00
12:00
13:00
14:00
15:00
16:00
17:00
18:00
19:00
20:00
21:00
22:00
23:00
